Sakura Sakajiri

Sakura Sakajiri

Auto-generated profile, based on publicly available information

Sakura Sakajiri

Juntendo Urayasu Hospital Urayasu Japan

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 March 2021 in Cancer Science
Verified
Journal Article
Open access
PDF file
STShunji Takahashi
Shunji Takahashi
YFYutaka Fujiwara
Yutaka Fujiwara
KNKenji Nakano
Kenji Nakano
TSToshio Shimizu
Toshio Shimizu
JTJunichi Tomomatsu
Junichi Tomomatsu
NYNoboru Yamamoto
Noboru Yamamoto
Milademetan (DS‐3032, RAIN‐32) is an orally available mouse double minute 2 (MDM2) antagonist with potential antineoplastic activity owing to increase in p53 activity through interruption of the MDM2‐p53 interaction. This phase I, dose‐escalating study assessed the safety, tolerability, efficacy, and pharmacokinetics of milademetan in 18 Japanese patients with solid tumors who relapsed after or were refractory to standard therapy. Patients aged ≥ 20 years received oral milademetan once daily (60 mg, n = 3; 90 mg, n = 11; or 120 mg, n = 4) on days 1 to 21 in a 28‐day cycle. Dose‐limiting toxicities, safety, tolerability, maximum tolerated dose, pharmacokinetics, and recommended dose for phase II were determined. The most frequent treatment‐emergent adverse events included nausea (72.2%), decreased appetite (61.1%), platelet count decreased (61.1%), white blood cell count decreased (50.0%), fatigue (50.0%), and anemia (50.0%). Dose‐limiting toxicities (three events of platelet count decreased and one nausea) were observed in the 120‐mg cohort. The plasma concentrations of milademetan increased in a dose‐dependent manner. Stable disease was observed in seven out of 16 patients (43.8%). Milademetan was well tolerated and showed modest antitumor activity in Japanese patients with solid tumors. The recommended dose for phase II was considered to be 90 mg in the once‐daily 21/28‐day schedule. Future studies would be needed to further evaluate the potential safety, tolerability, and clinical activity of milademetan in patients with solid tumors and lymphomas. The trial was registered with Clinicaltrials.jp: JapicCTI‐142693.

31 August 2019 in International Journal of Hematology
Verified
Journal Article
Closed access
PDF file
TTTakeshi Takahashi
Takeshi Takahashi
KUKensuke Usuki
Kensuke Usuki
KMKosei Matsue
Kosei Matsue
HOHitoshi Ohno
Hitoshi Ohno
TSToru Sakura
Toru Sakura
SSSakura Sakajiri
Sakura Sakajiri